Finanzen von Apimeds Pharmaceuticals US Inc (APUS)APUSApimeds Pharmaceuticals US Inc

Evaluating the bottom line, Apimeds Pharmaceuticals US Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -100.13%, provide a clear picture of how effectively APUS converts its operational activities into shareholder value.

In the context of the broader market, APUS competes directly with industry leaders such as BTAI and CVKD. With a market capitalization of $5.96M, it holds a leading position in the sector. When comparing efficiency, APUS's gross margin of N/A stands against BTAI's 87.91% and CVKD's N/A. Such benchmarking helps identify whether Apimeds Pharmaceuticals US Inc is trading at a premium or discount relative to its financial performance.

The company has shown consistent losses, with a net income of -35059852 in Q1 2026 and -20173129 in Q2 2026, indicating severe financial distress. The EPS for Q2 2026 is -117.74, reflecting ongoing losses.